azeliragon: Clinical Trials

7 trials of azeliragon, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 not yet recruiting, 1 recruiting. 7 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Active not recruiting 1, Completed 1, Not yet recruiting 1, Recruiting 1, Suspended 1, Unknown 1, Withdrawn 1
Phase 25Completed 1, Not yet recruiting 1, Recruiting 1, Suspended 1, Unknown 1

Follow azeliragon: new trials by email Literature Review of azeliragon trials Research Report on azeliragon

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer
Azeliragon, T-DXd - T-dxd Resistant HER2-Positive, HER2 Low Metastatic Breast Cancer
Phase 1 / Phase 2Not yet recruitingThe Methodist Hospital Research Institute272026-12-012026-08-25
Concurrent Azeliragon With Craniospinal Irradiation
Azeliragon, CSI - Solid Tumor, High-grade Glioma
Phase 1Active not recruitingNYU Langone Health212025-02-182026-05-18
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma
Azeliragon, Biospecimen Collection, Computed Tomography - Glioblastoma, Malignant Glioma
Phase 1WithdrawnCity of Hope Medical Center2024-11-152024-09-19
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Azeliragon, Stereotactic radiosurgery, Corticosteroid - Cancer, Metastasis
Phase 1 / Phase 2SuspendedBaptist Health South Florida462023-11-172026-06-16
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg - Glioblastoma
Phase 1 / Phase 2CompletedCantex Pharmaceuticals332023-09-052026-10-19
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
TTP488, ddAC/ddT, TC - Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
Phase 1 / Phase 2RecruitingGeorgetown University482023-06-062025-12-24
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
Azeliragon - Metastatic Pancreatic Cancer
Phase 1 / Phase 2UnknownCantex Pharmaceuticals302023-06-012024-06-14

Conditions studied

Glioblastoma (2)  ·  Glioma (2)  ·  Brain Neoplasms (1)  ·  Meningeal Carcinomatosis (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)  ·  Pancreatic Neoplasms (1)

Sponsors

Cantex Pharmaceuticals (2)  ·  Baptist Health South Florida (1)  ·  City of Hope Medical Center (1)  ·  Georgetown University (1)  ·  NYU Langone Health (1)  ·  The Methodist Hospital Research Institute (1)

Countries

United States (4)  ·  Spain (1)

Top investigators

Andrew Hendifar, MD (1)  ·  Candace Mainor, MD (1)  ·  Jana L Portnow (1)  ·  Jonathan Yang, MD, PhD (1)  ·  Minesh Mehta, M.D. (1)

Results publications

PMID 39744679

NIH funding

P30CA033572 (1), U19CA264512 (1)